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Iron is essential for life, yet excessive iron can damage tissues
and organs. To prevent iron deficiency and overload, iron
balance is regulated by the hormone hepcidin. Hepcidin
levels increase in response to iron sufficiency, decreasing
intestinal iron absorption and inhibiting release of iron from
stores and macrophages. Iron deficiency lowers hepcidin,
leading to enhanced iron absorption and mobilization of iron
from stores. Hepcidin is also increased by inflammation, and
has a major role in the anemia of chronic disease. Chronic
kidney disease (CKD) is associated with increased hepcidin
levels, and this likely contributes to the incidence and
severity of anemia, and resistance to erythropoiesis-
stimulating agents (ESAs). Elevated hepcidin contributes to
the dysregulation of iron homeostasis in CKD. In patients
with CKD, although parenteral iron in CKD can bypass some
of the iron-blocking effects of hepcidin, free iron and iron
stores increase, anemia is only partially corrected, and ESA
dose requirements remain significantly higher than
physiological replacement. Agents that lower hepcidin or
inhibit its actions may be effective strategies to restore
normal iron homeostasis, and overcome anemia of chronic
kidney disease. We review the regulation of hepcidin, its role
in CKD-related anemia, and discuss the potential for hepcidin
as a clinical marker, and several investigational methods to
lower hepcidin for treatment of anemia in CKD.
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Iron is an essential element, serving as a crucial component
of heme in hemoglobin and myoglobin, and an important
cofactor for many redox enzymes. Iron absorption, storage,
and circulation in the body are highly regulated to maintain
adequate iron, yet avoid iron overload. The last decade has
led to a series of discoveries expanding our knowledge of the
regulation of iron absorption and storage, and the mechan-
isms underlying disordered iron metabolism.
Hepcidin is a key regulatory protein, controlling intestinal
absorption of iron and its distribution throughout the
body.1,2 Produced by the liver, high-circulating hepcidin
reduces iron absorption in response to oral or intravenous
iron.2 Conversely, limited iron leads to low hepcidin levels,
which allows enhanced intestinal iron absorption and release
of storage iron (Figure 1). The kidney is the major route of
hepcidin clearance. Hepcidin, prohepcidin, and hepcidin
metabolites increase in chronic kidney disease (CKD) and are
very high in dialysis patients. Elevated hepcidin appears to
have a major role in the development and severity of anemia
in CKD. Consequently, there is great interest in hepcidin
assays as a diagnostic test, and targeting hepcidin as a
therapeutic treatment for anemia in CKD.
STRUCTURE, METABOLISM, AND REGULATION OF HEPCIDIN
Hepcidin is a 25-amino-acid protein with eight cysteine
residues and four disulfide bonds, which are highly conserved
across species.3 It is encoded by the HAMP gene, which
produces a 84-amino-acid preprohormone, which is cleaved
to 60-amino-acid prohepcidin, then the mature hormone
hepcidin-25.4
The major regulators of hepcidin blood levels are iron
status, anemia, hypoxia, and inflammation (Figure 1). Admin-
istration of oral and parenteral iron results in a rapid increase
in hepatic hepcidin mRNA levels and plasma hepcidin.5,6
Increased hepcidin levels then further downregulate intestinal
iron absorption, protecting against iron overload.
Transferrin-bound iron stimulates hepcidin expression by
hepatocytes.7 A bone morphogenic protein-6 (BMP-6)/
SMAD signaling pathway, which includes the proteins
hemojuvelin (HJV), the hemochromatosis protein HFE,
and transferrin receptor 2, mediate iron’s induction of
hepcidin gene transcription (Figure 2).4
Conversely, iron deficiency produces low hepcidin levels.
A liver transmembrane serine protease, known as TMPRSS6
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or matriptase-2, is required to suppress the hepcidin gene
under such conditions (Figure 2).8 This protease cleaves
and solubilizes HJV, downregulating the signaling of the
BMP-6/SMAD pathway mentioned above.9
Anemia and hypoxemia also leads to suppression of
hepcidin via separate signal pathways (Figure 2). Stimulation
of erythropoiesis with epoetin lowers hepcidin levels,
improving iron mobilization from stores, thus raising iron
availability to match demand.10,11 Epoetin’s suppressive effect
on hepcidin appears to be indirect, as blocking erythropoiesis
(such as via carboplatin or anti-epo antibodies) leads to an
increase in hepcidin, and therefore less mobilization of
iron.12 Hypoxia-inducible factor (HIF) mediates hypoxia
suppression of hepcidin (Figure 1).
Inflammation is the fourth major regulator, resulting in a
rapid increase in hepcidin and consequent induction of
hypoferremia. Interleukin (IL)-6 is the major inflammatory
cytokine mediating increased hepcidin.2,5 Administration of
lipopolysaccharide to healthy volunteers induces increased
IL-6 levels, followed by increased hepcidin, then hypoferre-
mia.13 Infusion of IL-6 into humans has similar effects.5
Overall, blood hepcidin levels change in a similar manner
to ferritin. Hepcidin and ferritin levels decrease with low iron
stores, and increase as storage iron increases. As similar to
ferritin, hepcidin increases with inflammation, confounding
the evaluation of iron status.14
REGULATION OF IRON HOMEOSTASIS BY HEPCIDIN
The major regulatory action of hepcidin is to bind to and
internalize the transmembrane iron efflux transporter,
ferroportin, which is present on enterocytes, macrophages,
and hepatocytes. Under normal conditions, iron enters the
body via absorption from the duodenum, and is lost only
through intestinal cell sloughing and blood loss.2
For iron to enter the circulation, following uptake into
enterocytes, ferroportin must be present in the basolateral
membrane, leading to iron entry and increased iron stores.
Conversely, increased hepcidin binds to and internalizes
ferroportin, preventing intestinal iron absorption, and
similarly reducing iron release from macrophages and
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Figure 1 | Iron (Fe) sufficiency and inflammation enhance
hepcidin production in the liver. Hepcidin in turn
downregulates surface expression of the ferroportin (FPN) in the
duodenum and reticuloendothelial stores, resulting in diminished
intestinal iron absorption, reduced iron release from iron stores,
and lower transferrin (TrFn) saturation. In contrast, stimulation of
erythropoiesis via exogenous epoetin or stabilization of hypoxia-
inducible factor (HIF), and iron deficiency suppresses hepatic
hepcidin production, resulting in intestinal iron absorption,
release of iron from stores, and higher transferrin saturation. Iron
is then cycled more efficiently to the bone marrow to support
erythropoiesis.
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Figure 2 | Signaling pathways for hepatic hepcidin transcription. Interleukin-6 (IL-6) binds to its receptor and in cooperation with the
Janus kinase (JAK) activates STAT3 signaling. For iron sufficiency to upregulate hepcidin production, transferring-bound iron binds to the
transferrin 1 receptor (TFR1), displacing HFE, the hemochromatosis gene product. HFE and transferring-bound iron bind to the transferrin 2
receptor and enhance hepcidin transcription either directly or in concert with the bone morphogenic protein-6 (BMP-6)/hemojuvelin (HJV)/
BMP receptor complex. Mutations in HFE, HJV, and TFR2 can disrupt iron-mediated hepcidin transcription, leading to progressive iron
overload. Iron deficiency impairs hepcidin transcription via the protease TMPRSS6 cleaving membrane-bound HJV, resulting in soluble HJV
(sHJV), which competitively impairs BMP receptor complex signaling.
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parenchymal iron stores.15 Clinically this results in low serum
iron, a decline in transferrin saturation, and diminishing iron
stores over time (Figure 1).
HEPCIDIN LEVELS IN CHRONIC KIDNEY DISEASE
Measurement of hepcidin level has been difficult.16 Some of
the problems with comparing assay methods and the lack of
standardization among methods are reviewed elsewhere.16,17
The most informative assays determine hepcidin-25
alone, and can be used on blood samples. Presently these
assays include surface-enhanced laser desorption/ionization
time-of-flight mass spectrometry, and enzyme-linked im-
munoassays.
The kidney is the major clearance pathway for hepcidin.
Not surprisingly then, multiple groups have demonstrated
that hepcidin is significantly elevated in patients on
dialysis.18–23 Most groups have found hepcidin levels directly
correlate with serum ferritin, and some report a correlation
with C-reactive protein, a marker of inflammation. Hepcidin
levels have been found to inversely correlate with epoetin
dose,19 and fall with initiation of epoetin therapy.22 These
relationships are consistent with the regulatory mechanisms
and relationships observed in animal studies.
In CKD stage 2–4, most studies and assay methods have
found hepcidin levels are intermediate to levels found in
normal controls and dialysis patients.19–22 In non-dialysis
CKD, hepcidin inversely correlates with estimated glomerular
filtration rate in some studies, but not in others.19–21 This
may be due to use of different assays, differing patient
comorbidities, and relatively small sample sizes.
HEPCIDIN AS A DIAGNOSTIC TEST IN CKD
A major diagnostic dilemma in managing CKD-related
anemia is determining whether patients need parenteral iron.
Studies examining ferritin, transferrin saturation, combina-
tions of those tests, and other tests have failed to find a
reliable predictor for iron response in dialysis and non-
dialysis CKD.24–26 As hepcidin is the true regulator of iron
stores, many have speculated that serum hepcidin might
better predict iron-restricted erythropoiesis.
Some data support a potential role for hepcidin in clinical
assessment of anemia. Investigators have repeatedly found a
relationship of ferritin to hepcidin levels in dialysis patients.
Ashby et al.19 found an inverse relationship of hepcidin level
to epoetin dose, and a decline in hepcidin upon initiating
epoetin, as did Weiss et al.22 These findings are consistent
with hepcidin being reflective of iron status and iron
demands in dialysis patients, and suggest hepcidin levels
could have predictive value in individuals.
However, other data undermine this view. Similar to
hepcidin, ferritin also correlates with iron status, but has a
high short-term intra-patient coefficient of variation and is
affected by inflammation.23 Ferritin has been repeatedly been
shown to lack adequate predictive value for identifying a
response to iron.27 Also, Kato et al.28 found hepcidin levels
were not different between epoetin-responsive and epoetin-
resistant dialysis patients, whereas Ford et al.23 found no
relationship of hepcidin with epoetin dose. In some studies,
hepcidin levels in dialysis patients correlate with C-reactive
protein, a marker of inflammation.21,23 It is precisely in
inflamed patients that the question of whether to administer
iron arises. Also, the intra-patient coefficient of variation for
hepcidin is even higher than for ferritin, undermining the
value of a single determination as indicative of iron status or
iron needs.23,27
Using an enzyme-linked immunoassay method, hepcidin
had greater intra-patient variability than ferritin in hemo-
dialysis patients, which indicates hepcidin assays are unlikely
to be a clinically useful diagnostic test in the anemia of CKD.
Consistent with this viewpoint, a recent study found
hepcidin levels, measured using a mass spectrometer method,
were not predictive of an erythropoietic response to IV iron
in hemodialysis patients.29
However, further investigation into the relationship of
assay methods to predictive value is needed. In stage 2–4
CKD, hepcidin may afford more diagnostic value, as values
are lower and may be more stable. Also, if interventions
eliminate or reduce the contribution of inflammation to
elevated hepcidin, levels of hepcidin may reflect iron stores
and provide clinical predictive value.
OVERCOMING HEPCIDIN-MEDIATED IRON BLOCKADE
Elevated hepcidin actively mediates iron-restricted erythro-
poiesis and contributes to anemia in CKD. Short-term
elevated hepcidin impairs release of storage iron, and long-
term elevated hepcidin can result in iron deficiency. In vitro
studies suggest elevated hepcidin may also directly contribute
to anemia in CKD by inhibiting erythroid colony formation
when erythropoietin concentrations are low, and impair red
blood cell survival.30 Consequently, overcoming the actions
of hepcidin could improve anemia or reduce erythropoiesis-
stimulating agent (ESA) requirements.
Parenteral iron, but not oral iron, improve the anemia-
induced overexpression of hepcidin.31–34 Studies in CKD and
dialysis patients show intravenous iron improved anemia in
most patients, including those with elevated hepcidin levels,29
and markedly elevated C-reactive protein levels.24,26
Although IV iron can apparently overcome some degree of
hepcidin-mediated iron blockade, there are several reasons to
be concerned. Iron therapy would increase hepcidin further,
enhancing later iron blockade. Consistent with continued
dysregulation of iron metabolism following IV iron, studies
show high liver-iron content in dialysis patients receiving IV
iron. The long-term effects of IV iron and enhanced iron
stores have not been rigorously investigated. Free iron
increases after IV iron administration, which may promote
infections and oxidative damage, whereas long-term,
cellular iron could accumulate because of persistently high
hepcidin levels. Consistent with continued dysregulation of
iron metabolism following IV iron, although ESA dose
requirements fall, they are significantly higher than physio-
logical replacement doses.
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Overexpression of hepcidin in animals impairs the
response to even supraphysiological doses of ESA.35 Thus,
high hepcidin levels may contribute to ESA resistance,
observed in many dialysis patients. Consequently, lowering
hepcidin or inhibiting its signaling would release iron from
stores, promote erythropoiesis, and prolong red cell survival,
and may be safer than high doses of ESAs with repetitive
parenteral iron.
Administration of an anti-hepcidin antibody has been
shown in an animal model expressing human hepcidin to
treat inflammation-induced anemia when combined with
ESA treatment.35 Interestingly, these animals did not
respond to IV iron in the absence of the neutralizing
antibody, indicating that the effects of the antibody are
mediated by factors beyond iron. Directly suppressing
hepcidin transcription via small-interfering RNA has also
been shown in preclinical studies to lower hepcidin, enhance
erythropoiesis, and increase in serum iron levels.35 Human
trials of this latter technology are expected to take place in the
coming year.
Membrane-bound HJV is a co-receptor for BMP, which in
turn binds to BMP receptor, translocates SMAD4 to the
nucleus, enhancing hepcidin expression in the liver. Mem-
brane-bound HJV can also bind to a membrane protein,
neogenin, and then be cleaved by the protease furin. This
soluble HJV competitively binds to BMP, preventing BMP
receptor signaling and suppressing hepcidin production.36
Thus, this pathway offers several potential targets for
downregulating hepcidin, including molecules, which mimic
soluble HJV, agents that block BMP receptor binding or
signaling, and agents that enhance cleavage of membrane-
bound HJV.
One such example is dorsomorphin, which is a small
molecule that inhibits BMP receptors. Dorsomorphin or
derivatives can reduce hepcidin expression in inflammatory
models, and may reduce the generalized inflammatory
response.37 Given the postulated role of chronic inflamma-
tion in CKD progression and cardiovascular outcomes,
agents, which alter BMP signaling, may have benefits, which
extend far beyond improving anemia.
Interruption of the IL-6 activation of the hepcidin gene
has been proposed as potential therapeutic avenue.8 Tocili-
zumab, a neutralizing antibody to IL-6, approved for
treatment of rheumatoid arthritis, lowers hepcidin levels
and improves anemia in Castleman’s disease, a lymphopro-
liferative disorder characterized by high levels of IL-6.38
Serious infections including tuberculosis are associated with
use of this agent in rheumatoid arthritis. Hepcidin has
in vitro antimicrobial activity, though it is unknown whether
lower hepcidin contributes to infection risks with this
antibody. Whether more graded inhibition of IL-6 signaling
could improve anemia in CKD while avoiding infection risks
is unknown.
Inhibition of the STAT3 has been shown to reduce
hepcidin expression in in vitro studies.39 Curcumin and
two other STAT3 inhibitors suppressed hepcidin gene
expression, even when stimulated by IL-6.39 Similarly, use
of small-interfering RNA to block STAT3 production,
suppressed hepcidin gene transcription. In vitro studies have
shown the STAT pathway is activated by oncostatin M and
leptin, whereas oncostatin M increases hepcidin in mice.40,41
These early studies suggest the STAT3 pathway may be a
potential target for hepcidin inhibition.
HIF suppresses hepcidin and enhances endogenous
erythropoietin production.42 Early human studies show
HIF prolyl hydrolylase inhibitors increase HIF, improve
anemia in CKD, enhance endogenous erythropoietin pro-
duction, and lower hepcidin. However, in at least some
models, stabilization of HIF enhances tumor growth. Clinical
trials continue with this class of agents. Other targets exist,
such as interruption of the binding of hepcidin to
ferroportin, which could enhance iron absorption and
mobilization.2,43
However, these investigational treatments for anemia in
CKD are not without risks. Sequestration of iron during
inflammation and infections may provide distinct benefits,
which may be negated by neutralizing the effects of hepcidin.
Lower serum iron and high hepcidin levels may be
antimicrobial. Consequently, reducing hepcidin levels in
CKD might promote infections. Interruption of BMP
signaling may suppress hepcidin but have other adverse
effects. Stabilization of HIF may improve anemia but
enhance tumor growth. We now know treatment of anemia
with ESA has very limited benefits and can be harmful,
though this harm is likely from other effects of ESA, not
anemia improvement per se. Each intervention intended to
overcome hepcidin blockade must be evaluated for safety
independently.
CONCLUSIONS
Hepcidin is the key regulator of iron balance, and high
hepcidin levels cause iron blockade and anemia in chronic
disease. Studies show CKD patients have high hepcidin levels,
likely contributing to anemia of CKD and ESA hyporespon-
siveness. Determination of hepcidin levels in CKD patients
may not provide more diagnostic value than ferritin, but
further studies are needed. Hepcidin and its regulatory
pathways are potential therapeutic targets, which could lead
to effective treatment of anemia of chronic disease and ESA
hyporesponsiveness in CKD.
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